Jnana Therapeutics

Jnana Therapeutics announced today that it has entered into an agreement to be acquired by Otsuka Pharmaceutical Co. By bringing together the strength of Jnana’s RAPID platform with Otsuka’s global capabilities and resources, the proposed transaction will further enable the development of novel therapies for under-addressed diseases, including JNT-517 for PKU. Upon completion of the acquisition later this year, Jnana will operate as a wholly owned subsidiary of Otsuka in Boston and continue its research and development. Read more: https://bit.ly/4ftndW9 #biotechnology #biopharma #acquisition

PKU is a rare, inherited metabolic disease that can cause progressive and severe neurological impairment and neuropsychological complications. There’s a critical need for a safe and efficacious treatment for individuals with PKU. This year, International PKU Day focuses on raising awareness about the lives of adults with PKU. Find out more at: https://www.espku.org/ #PKU #adultPKUawareness #PKUDAY2024

Our team joined the National PKU Alliance’s Move your Pheet for PKU challenge last month in honor of National PKU Awareness Month. We’ll help support the PKU community by strolling around the Seaport anytime! #PKU #raredisease

At #BIO2024 this week? Caroline Stark Beer, Chief Business Officer at Jnana, will be speaking on a panel titled “Exploring Deal-Making Options for Your Portfolio of Assets.”     The session will examine and discuss business development opportunities across a range of deal structures. Under Caroline’s leadership, Jnana has entered into two strategic collaborations with Roche.     More about the BIO panel here: https://bit.ly/4bKgZPv #biopharma #collaboration  

Proud to support the National PKU Alliance and the PKU community. #PKU

May is PKU Awareness Month. At Jnana, we understand the tremendous need for new treatments and are advancing JNT-517 in a clinical study in individuals with phenylketonuria (PKU). We’re encouraged by the clinical results shared to date and the potential of a new therapeutic to meet the critical need for an oral, safe, and efficacious therapy.   Read about our progress and the interim results from our ongoing study in #PKU: https://lnkd.in/dSkh2sZ2 #raredisease #clinicalstudy

Next week, CEO Joanne Kotz, Ph.D., will deliver a corporate presentation at the RBC Capital Markets Global Healthcare Conference on Tuesday, May 14th at 2:05pm ET. More here: bit.ly/3JTgiam #biotechnology #healthcare #drugdiscovery

Next week, CEO Joanne Kotz, Ph.D., will deliver a corporate presentation at the RBC Capital Markets Global Healthcare Conference on Tuesday, May 14th at 2:05pm ET. More here: bit.ly/3JTgiam #biotechnology #healthcare #drugdiscovery

Our team members recently spent a day volunteering together at The Greater Boston Food Bank. Currently, 1 in 3 Massachusetts residents face hunger, and we’re grateful for the opportunity to help make a difference in our community. #EndHungerHere

At the Society for Inherited Metabolic Diseases Annual Meeting next week, Jnana will present two posters on our SLC6A19 inhibitor program, including JNT-517, our first-in-class oral treatment in development for phenylketonuria (#PKU). Heike Wobst, Ph.D., Associate Director, Biology, and John Throup, Ph.D., SVP, Head of Development, will share insightful research on our clinical-stage lead program during a poster session on Monday, April 15th. https://bit.ly/3Q1ikJ4 #drugdevelopment #raredisease #genetics